The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Impact of EGFR mutation status in patients with completely resected lung adenocarcinoma treated with adjuvant platinum-based chemotherapy.
K. Yoh
No relevant relationships to disclose
K. Goto
No relevant relationships to disclose
S. Niho
No relevant relationships to disclose
H. Ohmatsu
No relevant relationships to disclose
K. Nagai
No relevant relationships to disclose
Y. Ohe
No relevant relationships to disclose